Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYB004 in Generalized Anxiety Disorder
NCT06051721Phase 2Completed
- Sponsor
- Cybin Inc.
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPL026 in generalized anxiety disorder (GAD) (2 arms), sponsored by Cybin Inc. Primary endpoint: Hamilton Anxiety Rating Scale at Day 364. Started May 2024; status: completed.
02
Drugs
SPL026
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06051721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051721.